Published research on PT-141 (bremelanotide): record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of other.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 0 recruiting, 1 active not recruiting, 9 completed.
Number of PubMed records mentioning PT-141 (bremelanotide), 2016 to 2026 (2026 is year to date).
Most recently started of 10 ClinicalTrials.gov entries.
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast MilkNCT06867835 · Completed · Phase 4 · started 2025-07-11A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityNCT06565611 · Active Not Recruiting · Phase 2 · started 2024-08-05A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseNCT05709444 · Completed · Phase 2 · started 2022-12-26A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)NCT04943068 · Completed · Phase 3 · started 2021-05-10Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire DisorderNCT04179734 · Completed · Phase 4 · started 2019-10-07Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With ZofranNCT03973047 · Completed · Phase 1 · started 2019-06-172. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderNCT02338960 · Completed · Phase 3 · started 2015-011. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderNCT02333071 · Completed · Phase 3 · started 2014-12Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderNCT01382719 · Completed · Phase 2 · started 2011-06Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)NCT00425256 · Completed · Phase 2 · started 2006-02Positive coverage and opinions: this section collects news and commentary that read favorably.
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight ManagementInnovent Biologics (via PR Newswire) · Jun 27, 2025Primary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.Front Med (Lausanne) · 2026 May 22 · Ashour AM · PubMedTherapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci · 2026 Apr 27 · Renke G et al. · PubMedNovel Pharmacologic Treatments of Female Sexual Dysfunction.Clin Obstet Gynecol · 2025 Jan 23 · How A et al. · PubMedPharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.Ann Pharmacother · 2024 May 20 · Barakeh D et al. · PubMedPharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?Expert Opin Pharmacother · 2022 Apr 18 · Nappi RE et al. · PubMedPharmacologic therapeutic options for sexual dysfunction.Curr Opin Obstet Gynecol · 2022 Dec 1 · Burton CS et al. · PubMedSafety Profile of Bremelanotide Across the Clinical Development Program.J Womens Health (Larchmt) · 2022 Feb · Clayton AH et al. · PubMedPhase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.Clin Ther · 2017 Feb 9 · Clayton AH et al. · PubMedEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.Int J Impot Res · 2004 Apr · Rosen RC et al. · PubMedDouble-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.Int J Impot Res · 2004 Feb · Diamond LE et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.